Association between serum corin levels and functional capacity in patients with advanced heart failure.

IF 1.9 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Biomarkers in medicine Pub Date : 2025-06-01 Epub Date: 2025-05-26 DOI:10.1080/17520363.2025.2511473

Murat Karaçam, Azmican Kaya, Seda Tanyeri, Ali Furkan Tekatlı, Süleyman Çagan Efe, Cem Doğan, Gülümser Sevgin Halil, Sinan Cerşit, Barkın Kültürsay, Kaan Kırali, Rezzan Deniz Acar

{"title":"Association between serum corin levels and functional capacity in patients with advanced heart failure.","authors":"Murat Karaçam, Azmican Kaya, Seda Tanyeri, Ali Furkan Tekatlı, Süleyman Çagan Efe, Cem Doğan, Gülümser Sevgin Halil, Sinan Cerşit, Barkın Kültürsay, Kaan Kırali, Rezzan Deniz Acar","doi":"10.1080/17520363.2025.2511473","DOIUrl":null,"url":null,"abstract":"Background: Corin is a cardiac protease that plays a role in transforming pro-natriuretic peptides into their active biological forms. This study aimed to investigate the relationship between serum corin levels and functional capacity in patients with advanced heart failure.Methods: This cross-sectional study included 88 consecutive patients with LVEF (Left ventricular ejection fraction) <25% who were referred to the tertiary cardiovascular center. Serum corin levels were measured using ELISA (Enzyme-linked immunosorbent assay) prior to CPET (Cardiopulmonary exercise testing). Multivariable linear regression was used to assess the independent association between serum corin levels and peak VO₂ (Peak oxygen consumption).Results: The mean age was 51.3 ± 12.2 years, and 86.4% were male. The mean peak VO₂ was 13.6 ± 3.99 mL/min/kg and the mean serum corin level was 1.7 ± 0.82 ng/mL. In multivariable analysis, serum corin level was an independent predictor of peak VO₂ (Coefficient: 1.206, 95% CI: 0.527-1.880, p = 0.0007).Conclusion: Lower serum corin levels are independently associated with reduced functional capacity in advanced heart failure. Corin may serve as a valuable biomarker to complement CPET in clinical evaluation, risk stratification, and treatment planning.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"395-403"},"PeriodicalIF":1.9000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12143726/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2025.2511473","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/26 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Corin is a cardiac protease that plays a role in transforming pro-natriuretic peptides into their active biological forms. This study aimed to investigate the relationship between serum corin levels and functional capacity in patients with advanced heart failure.

Methods: This cross-sectional study included 88 consecutive patients with LVEF (Left ventricular ejection fraction) <25% who were referred to the tertiary cardiovascular center. Serum corin levels were measured using ELISA (Enzyme-linked immunosorbent assay) prior to CPET (Cardiopulmonary exercise testing). Multivariable linear regression was used to assess the independent association between serum corin levels and peak VO₂ (Peak oxygen consumption).

Results: The mean age was 51.3 ± 12.2 years, and 86.4% were male. The mean peak VO₂ was 13.6 ± 3.99 mL/min/kg and the mean serum corin level was 1.7 ± 0.82 ng/mL. In multivariable analysis, serum corin level was an independent predictor of peak VO₂ (Coefficient: 1.206, 95% CI: 0.527-1.880, p = 0.0007).

Conclusion: Lower serum corin levels are independently associated with reduced functional capacity in advanced heart failure. Corin may serve as a valuable biomarker to complement CPET in clinical evaluation, risk stratification, and treatment planning.

查看原文本刊更多论文

晚期心力衰竭患者血清科林水平与功能能力的关系

背景：Corin是一种心脏蛋白酶，在将促利钠肽转化为其活性生物形式中起作用。本研究旨在探讨晚期心力衰竭患者血清corin水平与功能能力的关系。方法：本横断研究纳入连续88例LVEF（左室射血分数）患者。结果：平均年龄51.3±12.2岁，男性占86.4%。VO 2平均峰值为13.6±3.99 mL/min/kg，血清corin平均水平为1.7±0.82 ng/mL。在多变量分析中，血清corin水平是vo2峰值的独立预测因子（系数：1.206,95% CI: 0.527 ~ 1.880, p = 0.0007）。结论：较低的血清corin水平与晚期心力衰竭患者功能能力下降独立相关。Corin可以作为一种有价值的生物标志物，在临床评估、风险分层和治疗计划中补充CPET。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.